Checkpoint Therapeutics (NASDAQ:CKPT) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
Insider & Institutional Ownership
18.8% of Checkpoint Therapeutics shares are owned by institutional investors. 7.8% of Checkpoint Therapeutics shares are owned by insiders. Comparatively, 7.7% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings for Checkpoint Therapeutics and Esperion Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Checkpoint Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Esperion Therapeutics | 2 | 4 | 3 | 1 | 2.30 |
Checkpoint Therapeutics presently has a consensus price target of $17.6667, indicating a potential upside of 559.20%. Esperion Therapeutics has a consensus price target of $50.60, indicating a potential upside of 83.73%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Checkpoint Therapeutics is more favorable than Esperion Therapeutics.
Profitability
This table compares Checkpoint Therapeutics and Esperion Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Checkpoint Therapeutics | -2,032.05% | -100.54% | -75.09% |
| Esperion Therapeutics | -46.15% | -629.88% | -41.43% |
Risk and Volatility
Checkpoint Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
Valuation & Earnings
This table compares Checkpoint Therapeutics and Esperion Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Checkpoint Therapeutics | $1.71 million | 117.88 | $-24,710,000.00 | ($0.70) | -3.83 |
| Esperion Therapeutics | $148.36 million | 5.23 | $-97,170,000.00 | ($3.59) | -7.67 |
Checkpoint Therapeutics has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Checkpoint Therapeutics beats Esperion Therapeutics on 10 of the 14 factors compared between the two stocks.
